תשובה למתעיינים ב- Fatigue
Investigators Brochure (abstract) For clinical trials only Rambam Medical Center – Israel Point4Life™ Revised January 2004 Adjuvant/complementary treatment of cancer-related Fatigue for "non-organ specific cancer" and critically ill patients. Introduction Fatigue/asthenia is the most common symptom described by patients with cancer with a prevalence ranging from 60% to more than 90%, and many persist after cure of cancer. Perhaps no other symptom is more classically associated with cancer than fatigue. Furthermore fatigue is often cited as the most disruptive symptom of a patient's daily routine (5). The symptom accompanies surgery, chemotherapy, radiation therapy, and biologic response modifier therapy. Chemotherapy- and radiation-therapy-related fatigue may be associated with anemia or with an accumulation of cell destruction end products.[1,2] In the case of radiation therapy, fatigue may be caused by increased energy requirements to repair damaged epithelial tissue.[3 Adrenal insufficiency, in critically ill patients were the corticotropic axis is greatly activated causing cortisol concentration, should be considered as a major contributing factor (7). Adrenal insufficiency in critically ill patients were the corticotropic axis is greatly activated causing cortisol concentration that correlates with illness-severity and are highest in individuals with highest mortality (7).is also a major Fatigue (lack of energy, stamina, gastric pain, weight loss, nausea, vomiting, dizziness….) inducing factor that should be addressed when coming to treat it. (7) Because the etiology of cancer related fatigue is generally multifactoral the pharmaceutical management should, whenever possible, be directed toward etiology.(5) Point4Life™ is designed to answer to such, major, etiological factors namely: The regulation of "non-specific-stress", harmful, effects on the body's homeostatic mechanism. Indications: Point4Life™ is to be used as an adjuvant / complementary therapy to surgical, chemo and radiation therapies, and following marrow transplantation. Point4Life™is expected to increase body's nonspecific resistance to physical and mental stressors, protect body from harmful effects at cellular level and by thus to minimize fatigue symptoms generally associated with cancer and critical illnesses i.e. lack of energy, stamina, gastric pain, weight loss, nausea, vomiting, dizziness… References: 1. Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997. 2. Cella D, Mo F, Peterman A: Anemia, fatigue, and quality of life in people with cancer and HIV infection. [Abstract] Blood 88 (10 Suppl 1): A-571, 146a, 1996. 3. Haylock PJ, Hart LK: Fatigue in patients receiving localized radiation. Cancer Nurs 2(6): 461-467, 1979. 4. Reich SG: The tired patient: psychological versus organic causes. Hosp Med 22 (7): 142-154, 1986. 5. Roger Waltzman: Chalenges of Treating Cancer-Related Fatigue. Oncology – Special Edition (4): 35-39, 2001 6. Lillberg K, Vercasalo PK, et al: Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemol 2003 Mar 1:157(5):415-23 7. Wiebke Arlt, Bruno Allolio: Adrenal insufficiency. The Lancet 2003;361:1881-93 8. Gafney BT, Hugel HM, Rich PA. Panax G. and Eleutherococcus senticosus may exaggerate an already existing biphasic response to stress via inhibition of enzymes which limit the binding of stress hormones to their receptors. Medical Hypotheses 2001; 56(5): 567-572
Investigators Brochure (abstract) For clinical trials only Rambam Medical Center – Israel Point4Life™ Revised January 2004 Adjuvant/complementary treatment of cancer-related Fatigue for "non-organ specific cancer" and critically ill patients. Introduction Fatigue/asthenia is the most common symptom described by patients with cancer with a prevalence ranging from 60% to more than 90%, and many persist after cure of cancer. Perhaps no other symptom is more classically associated with cancer than fatigue. Furthermore fatigue is often cited as the most disruptive symptom of a patient's daily routine (5). The symptom accompanies surgery, chemotherapy, radiation therapy, and biologic response modifier therapy. Chemotherapy- and radiation-therapy-related fatigue may be associated with anemia or with an accumulation of cell destruction end products.[1,2] In the case of radiation therapy, fatigue may be caused by increased energy requirements to repair damaged epithelial tissue.[3 Adrenal insufficiency, in critically ill patients were the corticotropic axis is greatly activated causing cortisol concentration, should be considered as a major contributing factor (7). Adrenal insufficiency in critically ill patients were the corticotropic axis is greatly activated causing cortisol concentration that correlates with illness-severity and are highest in individuals with highest mortality (7).is also a major Fatigue (lack of energy, stamina, gastric pain, weight loss, nausea, vomiting, dizziness….) inducing factor that should be addressed when coming to treat it. (7) Because the etiology of cancer related fatigue is generally multifactoral the pharmaceutical management should, whenever possible, be directed toward etiology.(5) Point4Life™ is designed to answer to such, major, etiological factors namely: The regulation of "non-specific-stress", harmful, effects on the body's homeostatic mechanism. Indications: Point4Life™ is to be used as an adjuvant / complementary therapy to surgical, chemo and radiation therapies, and following marrow transplantation. Point4Life™is expected to increase body's nonspecific resistance to physical and mental stressors, protect body from harmful effects at cellular level and by thus to minimize fatigue symptoms generally associated with cancer and critical illnesses i.e. lack of energy, stamina, gastric pain, weight loss, nausea, vomiting, dizziness… References: 1. Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997. 2. Cella D, Mo F, Peterman A: Anemia, fatigue, and quality of life in people with cancer and HIV infection. [Abstract] Blood 88 (10 Suppl 1): A-571, 146a, 1996. 3. Haylock PJ, Hart LK: Fatigue in patients receiving localized radiation. Cancer Nurs 2(6): 461-467, 1979. 4. Reich SG: The tired patient: psychological versus organic causes. Hosp Med 22 (7): 142-154, 1986. 5. Roger Waltzman: Chalenges of Treating Cancer-Related Fatigue. Oncology – Special Edition (4): 35-39, 2001 6. Lillberg K, Vercasalo PK, et al: Stressful life events and risk of breast cancer in 10,808 women: a cohort study. Am J Epidemol 2003 Mar 1:157(5):415-23 7. Wiebke Arlt, Bruno Allolio: Adrenal insufficiency. The Lancet 2003;361:1881-93 8. Gafney BT, Hugel HM, Rich PA. Panax G. and Eleutherococcus senticosus may exaggerate an already existing biphasic response to stress via inhibition of enzymes which limit the binding of stress hormones to their receptors. Medical Hypotheses 2001; 56(5): 567-572